C. Avendaño

5.2k total citations · 1 hit paper
99 papers, 2.4k citations indexed

About

C. Avendaño is a scholar working on Public Health, Environmental and Occupational Health, Organic Chemistry and Economics and Econometrics. According to data from OpenAlex, C. Avendaño has authored 99 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Public Health, Environmental and Occupational Health, 17 papers in Organic Chemistry and 17 papers in Economics and Econometrics. Recurrent topics in C. Avendaño's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Speech and Audio Processing (12 papers) and Advanced Adaptive Filtering Techniques (9 papers). C. Avendaño is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Speech and Audio Processing (12 papers) and Advanced Adaptive Filtering Techniques (9 papers). C. Avendaño collaborates with scholars based in Spain, United States and United Kingdom. C. Avendaño's co-authors include Richard O. Duda, V. Ralph Algazi, David M. Thompson, Hynek Heřmanský, JH Morrison, DG Amaral, Fernando Reinoso‐Suárez, José Antonio Sacristán, Pilar Garrido and Juan Blanco and has published in prestigious journals such as Science, JAMA and Journal of Neuroscience.

In The Last Decade

C. Avendaño

95 papers receiving 2.3k citations

Hit Papers

The CIPIC HRTF database 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The CIPIC HRTF database
    2002 611 citations C. Avendaño et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Avendaño Spain 23 791 675 258 235 211 99 2.4k
Dongxin Xu United States 20 337 0.4× 199 0.3× 79 0.3× 64 0.3× 288 1.4× 57 3.2k
H. Mohseni Iran 24 644 0.8× 267 0.4× 72 0.3× 18 0.1× 196 0.9× 79 2.9k
Mark White United States 24 832 1.1× 179 0.3× 161 0.6× 18 0.1× 70 0.3× 98 2.1k
Mark M. Stecker United States 36 499 0.6× 30 0.0× 440 1.7× 25 0.1× 316 1.5× 183 4.8k
David M. Rapoport United States 47 2.3k 3.0× 181 0.3× 75 0.3× 6 0.0× 681 3.2× 179 9.6k
Charles L. Feldman United States 36 199 0.3× 43 0.1× 55 0.2× 166 0.7× 332 1.6× 101 7.8k
Joachim A. Behar Israel 28 944 1.2× 569 0.8× 64 0.2× 35 0.1× 73 0.3× 96 2.9k
Yixin Fang United States 29 217 0.3× 55 0.1× 12 0.0× 36 0.2× 186 0.9× 113 2.1k
Xiao Hu United States 33 403 0.5× 101 0.1× 425 1.6× 21 0.1× 383 1.8× 209 3.7k
David Levin United States 24 462 0.6× 41 0.1× 178 0.7× 119 0.5× 67 0.3× 107 2.2k

Countries citing papers authored by C. Avendaño

Since Specialization
Citations

This map shows the geographic impact of C. Avendaño's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Avendaño with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Avendaño more than expected).

Fields of papers citing papers by C. Avendaño

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Avendaño. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Avendaño. The network helps show where C. Avendaño may publish in the future.

Co-authorship network of co-authors of C. Avendaño

This figure shows the co-authorship network connecting the top 25 collaborators of C. Avendaño. A scholar is included among the top collaborators of C. Avendaño based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Avendaño. C. Avendaño is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martı́n, Francisco, Gloria Carmona, Josep M. Canals, et al.. (2025). Regulatory Strategies for Accelerating the Translation of Gene Therapies to Clinical Practice: Focus on GMO Considerations. Human Gene Therapy. 36(17-18). 1154–1158. 1 indexed citations
2.
Payares‐Herrera, Concepción, Rosa Malo de Molina, Trinidad Martín-Donaire, et al.. (2024). Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial. Bone Marrow Transplantation. 59(6). 777–784. 5 indexed citations
3.
García‐Pérez, Javier, Mercedes Bermejo, Erick De La Torre Tarazona, et al.. (2023). Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology. 95(3). e28679–e28679. 3 indexed citations
4.
Romera, Irene, José Antonio García‐Erce, Cristina Arbona, et al.. (2023). Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID‐19 convalescent plasma. Vox Sanguinis. 118(4). 296–300. 1 indexed citations
5.
Santucci, Claudia, Beatríz González López-Valcarcel, C. Avendaño, et al.. (2023). Gender inequity in the medical profession: the women doctors in Spain (WOMEDS) study. Human Resources for Health. 21(1). 77–77. 6 indexed citations
6.
Ruíz‐Antorán, Belén, Alicia Gómez‐López, Aránzazu Sancho‐López, et al.. (2022). Bronchopulmonary Penetration of Isavuconazole in Pulmonary Transplant Recipients (PBISA01): Protocol for a Phase IV Clinical Trial With a Single Treatment Arm. JMIR Research Protocols. 11(9). e37275–e37275.
7.
8.
Dal‐Ré, Rafael, C. Avendaño, Brigitte Bloechl‐Daum, et al.. (2019). Low risk pragmatic trials do not always require participants’ informed consent. BMJ. 364. l1092–l1092. 23 indexed citations
9.
Gratacós, Jordi, Caridad Pontes, Xavier Juanola, et al.. (2019). Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Research & Therapy. 21(1). 11–11. 39 indexed citations
10.
Annese, Vito, C. Avendaño, Ferdinand C. Breedveld, et al.. (2016). Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016. Generics and Biosimilars Initiative Journal. 5(2). 74–83. 12 indexed citations
11.
Sacristán, José Antonio, et al.. (2016). Patient involvement in clinical research: why, when, and how. Patient Preference and Adherence. 10. 631–631. 211 indexed citations
12.
13.
Gómez‐Outes, Antonio, C. Avendaño, Ana Isabel Terleira‐Fernández, & Emilio Vargas. (2014). Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain. PharmacoEconomics. 32(9). 919–936. 18 indexed citations
14.
Gómez‐Barrena, Enrique, C. Avendaño, & Carmen Bunu. (2014). Regulatory authorities and orthopaedic clinical trials on expanded mesenchymal stem cells. International Orthopaedics. 38(9). 1803–1809. 12 indexed citations
15.
Avendaño, C., et al.. (2012). Cambios en la normativa europea de ensayos clínicos (ii): por una regulación proporcionada y adaptada al riesgo. Medicina Clínica. 138(13). 574–578. 1 indexed citations
16.
Avendaño, C. & J. Carlos Menéndez. (2007). Peptidomimetics in cancer chemotherapy. Clinical & Translational Oncology. 9(9). 563–570. 6 indexed citations
17.
Reiser, Markus, Holger Hinrichsen, Yves Benhamou, et al.. (2005). Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C†‡. Hepatology. 41(4). 832–835. 121 indexed citations
18.
Avendaño, C., et al.. (2003). Comités éticos de investigación clínica y «dictamen único» de los ensayos clínicos multicéntricos. Medicina Clínica. 120(5). 180–188. 3 indexed citations
19.
Carceller, Fernando, et al.. (1999). Hippocampal cell loss in transient global cerebral ischemia in rats: a critical assessment. Neuroscience. 93(1). 71–80. 31 indexed citations
20.
Avendaño, C., et al.. (1991). Interference of Digoxin-Like Immunoreactive Substances with TDx Digoxin II Assay in Different Patients. Therapeutic Drug Monitoring. 13(6). 523–527. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dongxin Xu Breakdown of academic impact, for papers by H. Mohseni Breakdown of academic impact, for papers by Mark White Breakdown of academic impact, for papers by Mark M. Stecker Breakdown of academic impact, for papers by David M. Rapoport Breakdown of academic impact, for papers by Charles L. Feldman Breakdown of academic impact, for papers by Joachim A. Behar Breakdown of academic impact, for papers by Yixin Fang Breakdown of academic impact, for papers by Xiao Hu Breakdown of academic impact, for papers by David Levin
Rankless by CCL
2026